Studies with SLAMF7-specific CARs confirmed the suitability of SLAMF7 as a potential target in Multiple myeloma (MM). Both NK cells and T cells expressing second-generation CARs based on a single chain variable fragment of an antibody related to elotuzumab effectively redirected NK and T cells to secrete cytokines, degranulate and exhibit cytotoxic activity in response to MM cell lines and primary human myeloma cells in vitro. SLAMF7-directed NK and T cells also inhibited tumor growth and prolonged survival in an orthotopic MM xenograft mouse model.
Drug targets for cancer: SLAMF7 research reagents
Other vital drug targets for cancer likeSLAMF7:
Einsele H, Schreder M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Therapeutic Advances in Hematology. 2016;7(5):288-301.